United States Patent 9,597,284: Scope, Claims, Expiration and Varenicline Dry-Eye Patent Landscape

US Patent No. 9,597,284 protects intranasal treatment of dry eye with varenicline, a nicotinic acetylcholine receptor agonist, at a low local dose designed to activate peripheral pathways without meaningful central nervous system exposure. The patent is directed to the therapeutic method, not merely to varenicline, a nasal device, or a formulation. Its central commercial relevance is Tyrvaya, the varenicline nasal spray approved by the FDA for the treatment of signs and symptoms of dry eye disease.

The patent’s statutory expiration is June 12, 2029, based on the earliest claimed priority date, subject to any applicable patent-term adjustment or extension. The patent creates a principal method-of-use barrier for a generic intranasal varenicline product that follows the Tyrvaya labeling.

What does US Patent 9,597,284 protect?

US 9,597,284 protects a method of treating dry eye by administering varenicline into the nasal cavity at a dose of 5 to 50 micrograms per dose. The claim requires all of the following elements:

Claim element	Scope
Disease	Dry eye
Active ingredient	Varenicline
Route	Local administration into the nasal cavity
Dose	5 to 50 micrograms per dose
Pharmacology	Selective binding to peripheral nicotinic acetylcholine receptors
CNS exposure	No pharmacologically relevant blood-brain-barrier penetration
Safety profile	No undesired psychoactive or systemic side effects
Mechanism	Optional activation of trigeminal and nasolacrimal reflex pathways

Claim 1 is the commercial core of the patent. It is narrower than a claim covering all nicotinic receptor agonists because the claim expressly requires that the agonist be varenicline. It is also narrower than a claim covering all ophthalmic or nasal dry-eye therapies because it requires intranasal delivery and a defined dose range.

The patent does not claim every use of varenicline. A use outside dry-eye treatment, a non-nasal route, or a dose outside the claimed range would not literally satisfy claim 1. The dependent claims create additional coverage for receptor subtype activity, administration frequency, dosage forms, delivery devices, receptor desensitization control, and reflex-mediated mechanisms. (U.S. Patent No. 9,597,284, 2017).

How broad is claim 1 of US 9,597,284?

Claim 1 is a product-specific method claim with several cumulative limitations. A potential infringing use must generally meet each required limitation.

Varenicline requirement

The claim requires varenicline. A different nicotinic acetylcholine receptor agonist would not literally infringe claim 1, even if it were administered intranasally for dry eye at the same dose. Earlier or related patent claims may have pursued broader agonist classes, but the issued claim supplied in the question is limited to varenicline.

This limitation materially narrows the patent’s scope. It also makes the claim commercially important because varenicline is the active ingredient in Tyrvaya.

Intranasal delivery requirement

The drug must be administered into the nasal cavity. The claim does not cover conventional topical ophthalmic administration into the eye. A formulation administered orally, intravenously, subcutaneously, or directly to the ocular surface would fall outside the literal route limitation.

The dependent claims expand the practical device coverage to nasal administration through:

A syringe or dropper
A bottle nebulizer
An atomization pump
An inhaler
A powder spray device
A vaporizer
A patch
A medicated stick
A pipette
A jet of liquid

The claim language is broad as to delivery hardware. It does not require a particular pump, nozzle, container, or spray geometry.

Dose limitation

Claim 1 requires a non-systemically bioavailable dose between 5 and 50 micrograms per dose. This dose limitation is central to infringement analysis.

Tyrvaya is labeled as varenicline nasal spray 0.03 mg per spray, or 30 micrograms per spray, with one spray in each nostril twice daily. That labeled dose falls within the 5-to-50-microgram range in claim 1. (FDA, 2021).

A product administered at more than 50 micrograms per dose could avoid literal infringement of claim 1, although other patents, doctrine-of-equivalents arguments, or separate claims could remain relevant. A product below 5 micrograms per dose presents the same issue.

Peripheral receptor and blood-brain-barrier limitations

The claim requires selective binding to a peripheral nicotinic acetylcholine receptor and no pharmacologically relevant concentration crossing the blood-brain barrier. These limitations distinguish the claimed treatment from centrally acting nicotinic agonists associated with psychoactive effects.

The receptor limitation is functional rather than purely structural. In litigation, the parties would likely contest:

Which receptor subtypes are covered
What “selectively binds” means
Whether selectivity is measured by affinity, activity, or functional response
What concentration is pharmacologically relevant
Whether nasal administration produces sufficient peripheral exposure
Whether the accused product causes meaningful central exposure

What do claims 2 through 15 add?

The dependent claims divide into five principal coverage groups.

Receptor subtype claims

Claim 2 identifies alpha3beta4, alpha4beta2, and alpha7 nicotinic acetylcholine receptor subtypes. Varenicline has recognized activity at several nicotinic receptor subtypes, including alpha4beta2 and alpha3beta4 receptors. The claim does not require binding to all three subtypes. The phrase “at least one” makes the limitation alternative in nature.

Side-effect limitations

Claims 3 and 4 require an amount that does not result in undesired psychoactive or systemic side effects. These limitations support the patent’s distinction between local peripheral activity and central nervous system exposure.

They also create potential litigation questions. “Undesired” is context-dependent, and the specification, prosecution history, clinical evidence, and product labeling would likely inform claim construction. Adverse events such as sneezing, cough, throat irritation, or dysgeusia would not automatically establish a claimed systemic or psychoactive effect.

Receptor desensitization claims

Claims 5 through 7 cover coadministration of substances intended to prevent or reduce nicotinic receptor desensitization or accelerate recovery from the desensitized state.

Claim 7 identifies:

Cyclosporine
Pimecrolimus
Tacrolimus

Claims 5 and 6 also refer to PKC, PKA, factors that upregulate or modulate those kinases, and calcineurin inhibitors. These claims could reach combination regimens in which varenicline is administered with an immunomodulator or another agent intended to preserve receptor responsiveness.

The claims do not appear limited to a particular fixed-dose combination. Separate administration could potentially satisfy the claims if the required coadministration and functional purpose are established.

Dosing-frequency claims

Claims 8 through 10 cover administration:

At least once daily
At least twice daily
At least once weekly

The claims are drafted as alternatives. Tyrvaya’s labeled regimen of one spray per nostril twice daily is within the daily and twice-daily concepts, assuming the dosage is evaluated per spray or per administration in the manner required by the claim construction.

The weekly claim is broader in frequency but may face enablement and written-description scrutiny if challenged over the full scope of weekly regimens, dose amounts, and clinical outcomes.

Formulation and device claims

Claim 11 covers liquid, suspension, aerosol, gel, ointment, dry powder, cream, paste, lotion, or balm. Claim 12 covers numerous delivery mechanisms.

These claims are not limited to the exact Tyrvaya spray presentation. A competing intranasal varenicline formulation could remain within the patent even if it used a different physical dosage form or device.

Neural-reflex claims

Claims 13 through 15 require activation of:

The trigeminal nerve
The anterior ethmoidal nerve
The nasolacrimal reflex

These limitations tie the treatment effect to the proposed nasal sensory pathway connecting nasal stimulation with lacrimal secretion. They may be difficult to prove directly in a generic case because the mechanism may be established through pharmacology, clinical data, labeling, or expert testimony rather than routine batch-release testing.

When does US 9,597,284 expire?

Event	Date or status
Patent grant	March 21, 2017
Patent number	US 9,597,284
Core subject matter	Intranasal varenicline treatment of dry eye
Statutory expiration	June 12, 2029
Relevant FDA product	Tyrvaya, varenicline nasal spray
Regulatory pathway	FDA NDA 214908
FDA approval	October 15, 2021

The patent term is calculated from the earliest applicable nonprovisional priority date rather than from the grant date. Patent-term adjustment or a patent-term extension could alter the effective expiration date. The principal commercial exclusivity issue is the relationship between the patent and the FDA-approved Tyrvaya labeling.

The patent’s expiration date is separate from FDA regulatory exclusivity. FDA new-drug exclusivity, if available, does not necessarily expire on the same date as the patent and does not itself extend the patent term.

What is the Orange Book status of US 9,597,284?

US 9,597,284 is associated with Tyrvaya’s FDA-approved varenicline nasal spray and is relevant to Orange Book patent analysis. An Orange Book listing can provide the basis for a generic applicant to make a Paragraph IV certification if the applicant seeks approval before the listed patent expires.

The listing does not mean that every claim in the patent covers every possible varenicline product. Orange Book relevance is tied to the approved drug product and the patent’s asserted relationship to the approved method, formulation, or use.

For an ANDA applicant, the main question is whether the proposed labeling includes a use that falls within the patented dry-eye method. A “skinny label” strategy could remove a patented indication only if the remaining labeling and marketing do not induce infringement.

What Paragraph IV challenges and generic entry risks exist?

A generic applicant seeking approval for intranasal varenicline could use several possible strategies:

Strategy	Principal risk
Paragraph IV challenge	Patent litigation and possible 30-month stay
Wait for patent expiration	Delayed entry until 2029 or later
Design-around dose	Clinical equivalence and patent coverage risk
Different nasal device	Claims 11 and 12 may still cover the product
Different administration frequency	Claims 8-10 may still apply
Skinny labeling	Induced-infringement and regulatory-labeling risk
Non-varenicline agonist	Different efficacy, safety, and approval burden

For a direct generic of Tyrvaya, the central risk is claim 1. A product with varenicline, nasal administration, dry-eye labeling, and a 5-to-50-microgram dose would closely track the claim language.

A Paragraph IV challenge could target:

Anticipation by earlier publications or patents
Obviousness based on intranasal nicotinic agonists and dry-eye treatment
Lack of written description for the full claim scope
Enablement of the dose, receptor, and mechanistic limitations
Indefiniteness of terms such as “selectively,” “pharmacologically relevant concentration,” and “undesired” effects
Patent-term or Orange Book listing defects

The patent’s strongest infringement position is against a product that copies the Tyrvaya label. Its more vulnerable areas are functional limitations and the breadth of dependent claims covering receptor modulation, broad formulations, delivery devices, and weekly administration.

Which companies are challenging the patent?

The supplied patent and claim set do not establish a named Paragraph IV challenger or a reported settlement involving US 9,597,284. The public litigation risk should be evaluated through FDA Paragraph IV notices, district-court dockets, assignment records, and Orange Book updates.

Viatris is the principal commercial company associated with the Tyrvaya business following its acquisition of Oyster Point Pharma. The relevant competitive group includes:

Viatris and the Tyrvaya product
AbbVie, through Restasis and related cyclosporine products
Bausch + Lomb and other suppliers of cyclosporine-based dry-eye products
Novartis, through Xiidra, subject to ownership and commercial arrangements
Generic manufacturers pursuing conventional dry-eye therapies

These products compete clinically but do not necessarily create direct patent overlap with the claims of US 9,597,284.

How does US 9,597,284 compare with competing dry-eye patent estates?

Product or class	Active ingredient	Administration	Primary mechanism	Relationship to US 9,597,284
Tyrvaya	Varenicline	Intranasal	Peripheral nicotinic receptor stimulation and nasolacrimal reflex	Directly aligned
Restasis	Cyclosporine	Ophthalmic	Immunomodulation and increased tear production	Competing product, different route and active
Xiidra	Lifitegrast	Ophthalmic	LFA-1/ICAM-1 pathway inhibition	Competing product, different mechanism
Miebo	Perfluorohexyloctane	Ophthalmic	Tear-film lipid-layer treatment	Competing product, different mechanism
Generic artificial tears	Various	Ophthalmic	Lubrication	Outside the claim scope

The patent is differentiated by route and mechanism. It covers a nasal neural stimulation approach rather than an ocular anti-inflammatory or tear-film replacement therapy.

How strong is the patent estate for Tyrvaya?

US 9,597,284 is commercially strong against a straightforward generic because claim 1 tracks the product’s principal clinical use, active ingredient, route, and dose. The claim is narrower than a genus claim but more directly connected to the approved product.

Strengths

Direct alignment with the approved intranasal varenicline indication
Dose range covering the marketed dose
Specific identification of varenicline
Dependent claims covering multiple nasal dosage forms and devices
Method-of-use coverage that may support Orange Book listing

Vulnerabilities

Functional receptor-selectivity limitations
Potential indefiniteness disputes
Possible obviousness combinations involving varenicline, nicotinic receptors, nasal delivery, and dry-eye treatment
Questions concerning enablement across all listed dosage forms and frequencies
Difficulty proving neural-reflex activation in an ANDA infringement case
Limited coverage of non-varenicline nicotinic agonists

The broader commercial patent estate may include later patents directed to varenicline formulations, devices, concentrations, or methods. Those later rights must be analyzed separately from US 9,597,284 and should not be assumed to have the same expiration date.

What manufacturing and intellectual-property barriers affect generic entry?

Manufacturing a chemically equivalent varenicline nasal spray is unlikely to be the only entry barrier. A competitor must also address:

Varenicline tartrate or another pharmaceutically acceptable form
Impurity and degradation control
Nasal-spray dose uniformity
Container-closure compatibility
Preservative and excipient selection
Pump or atomizer performance
Local tolerability
Bioequivalence or comparable clinical performance
Labeling for the patented dry-eye use
Orange Book-listed patents and any later patent families

The patent does not appear to claim every manufacturing process for varenicline nasal spray. Manufacturing-process patents, device patents, formulation patents, and trade secrets could still affect practical entry.

Key Takeaways

US 9,597,284 claims intranasal varenicline for dry-eye treatment.
Claim 1 requires varenicline, nasal administration, a 5-to-50-microgram dose, peripheral receptor activity, and limited CNS exposure.
Tyrvaya’s labeled 30-microgram-per-spray regimen falls within the principal dose range.
The patent’s statutory expiration is June 12, 2029, subject to any applicable term adjustment or extension.
Claims 5 through 7 cover combinations intended to reduce nicotinic receptor desensitization.
Claims 11 and 12 extend coverage across broad nasal formulations and delivery devices.
Claims 13 through 15 cover trigeminal, anterior ethmoidal, and nasolacrimal-reflex mechanisms.
A direct generic Tyrvaya product would face a material infringement risk under claim 1.
The main validity issues are obviousness, enablement, written description, and indefiniteness of functional limitations.
No named Paragraph IV challenger or settlement is established by the supplied record.

Frequently Asked Questions

Does US 9,597,284 cover all uses of varenicline?

No. It covers a specific method involving intranasal administration of varenicline for dry eye at the claimed dose and with the stated peripheral pharmacology.

Does the patent cover an ophthalmic varenicline eye drop?

Not literally under the supplied claims. Claim 1 requires administration into the nasal cavity.

Would a 60-microgram intranasal varenicline dose avoid claim 1?

It could avoid the literal 5-to-50-microgram dose limitation, but infringement would depend on claim construction, other patent claims, and any doctrine-of-equivalents analysis.

Are Restasis and Xiidra covered by US 9,597,284?

No. Restasis and Xiidra use different active ingredients, routes, and mechanisms.

Can a generic manufacturer launch intranasal varenicline before June 2029?

Potentially, but it would need to overcome applicable Orange Book patents through a successful challenge, a non-infringing design, a settlement, or another lawful regulatory pathway.

References

U.S. Patent No. 9,597,284. (2017). Methods of treating dry eye using nicotinic acetylcholine receptor agonists. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2021). Tyrvaya (varenicline solution) nasal spray prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
U.S. Code, Title 35, §§ 154, 271, and 282. (2024). Patent term, infringement, and defenses.
U.S. Food and Drug Administration. (2024). Approved drug product and patent listing resources. FDA.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Oyster Point Pharma	TYRVAYA	varenicline tartrate	SPRAY;NASAL	213978-001	Oct 15, 2021		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015336216	⤷ Start Trial
Australia	2020213351	⤷ Start Trial
Brazil	112017008097	⤷ Start Trial
Canada	2965129	⤷ Start Trial
China	107106542	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,597,284

Which drugs does patent 9,597,284 protect, and when does it expire?

Summary for Patent: 9,597,284